DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren Tesh, PharmD, BCPS
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Harold J. Burstein, MD, PhD
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Bernard F. Cole, PhD
Professor
Department of Mathematics and Statistics
University of Vermont
Burlington, Vermont

Heidi D. Klepin, MD, MS
Associate Professor of Internal Medicine
Section of Hematology and Oncology
Wake Forest University Health Sciences
Winston Salem, North Carolina

Grzegorz S. Nowakowski, MD
Associate Professor of Medicine and Oncology
Mayo Clinic Rochester
Rochester, Minnesota

Vassiliki A. Papadimitrakopoulou, MD
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Department of Thoracic Head & Neck Medical Oncology
Division of Cancer Medicine
Houston, Texas

Courtney J. Preusse, MA
(Consumer Representative)
Research Administrator and Patient Advocate
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Gregory J. Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
Associate Professor, Weill Cornell Medical College
New York, New York

Brian I. Rini, MD, FACP
(Acting Chairperson)
Professor of Medicine, Lerner College of Medicine
Leader, GU Program
Department of Hematology and Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting) (cont.)

**Thomas S. Uldrick, MD, MS**
Clinical Director  
HIV & AIDS Malignancy Branch  
Center for Cancer Research  
National Cancer Institute  
Bethesda, Maryland

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

**Phuong Khanh (P.K.) Morrow, MD, FACP**
Executive Medical Director, Amgen Oncology  
Therapeutic Area Head, US Medical Organization  
Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

**Ralph B. D’Agostino, Sr., PhD**  
Professor of Mathematics/Statistics, Epidemiology and Biostatistics  
Mathematics and Statistics Department  
Boston University  
Boston, Massachusetts

**Courtney FitzHugh, MD**  
*Participation in afternoon session*  
Investigator  
Laboratory of Early Sickle Mortality Prevention  
Sickle Cell Branch, Division of Intramural Research  
National Heart, Lung, and Blood Institute  
National Institutes of Health (NIH)  
Bethesda, Maryland

**Stanley Lipkowitz, MD, PhD**  
*Participation in morning session*  
Chief  
Women’s Malignancy Branch  
Center for Cancer Research  
National Cancer Institute, NIH  
Bethesda, Maryland

**Michael E. Menefee, MD**  
*Participation in afternoon session*  
Assistant Professor of Oncology  
Division of Hematology and Oncology  
Mayo Clinic  
Jacksonville, Florida

**Shirley H. Miller, MA**  
*Participation in afternoon session*  
*Patient Representative*  
Manager, Community Programs  
Sickle Cell Disease Program  
Carolinas Healthcare System  
Charlotte, North Carolina

**Lori M. Minasian, MD, FACP**  
*Participation in morning session*  
Deputy Director  
Division of Cancer Prevention  
Investigator, Women’s Malignancy Branch  
National Cancer Institute, NIH  
Bethesda, Maryland
TEMPORARY MEMBERS (Voting) (cont.)

Stacy Nerenstone, MD  
(Participation in morning session)  
Assistant Clinical Professor of Medicine  
University of Connecticut  
Senior Physician  
Department of Medicine  
Medical Staff President  
Hartford Hospital  
Hartford, Connecticut

Andrew D. Seidman, MD  
(Participation in morning session)  
Attending Physician  
Breast Cancer Medicine Service  
Associate Chair, Academic Administration  
Department of Medicine  
Memorial Sloan Kettering Cancer Center  
Professor of Medicine  
Weill Cornell Medical College  
New York, New York

Patricia A. Spears, BS  
(Participation in morning session)  
(Patient Representative)  
Raleigh, North Carolina

Melanie E. Rovce, MD, PhD  
(Participation in morning session)  
Consultant, Breast Cancer Specialist  
Immediate Past Director of the Breast Clinic and former Professor  
University of New Mexico Comprehensive Cancer Center  
Albuquerque, New Mexico

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD  
Director  
Office of Hematology Oncology Products (OHOP)  
Office of New Drugs (OND), CDER, FDA

Julia Beaver, MD  
(Participation in morning session)  
Acting Director  
Division of Oncology Products 1 (DOP1)  
OHOP, OND, CDER, FDA

Laleh Amiri-Kordestani, MD  
(Participation in morning session)  
Medical Team Leader  
Breast Cancer Group  
DOP1, OHOP, OND, CDER, FDA

Harpreet Singh, MD  
(Participation in morning session)  
Medical Officer  
DOP1, OHOP, OND, CDER, FDA

Amanda Walker, MD  
(Participation in morning session)  
Medical Officer  
DOP1, OHOP, OND, CDER, FDA

Joyce Cheng, PhD  
(Participation in morning session)  
Statistical Reviewer  
Division of Biometrics V (DBV)  
Office of Biometrics (OB)  
Office of Translational Science (OTS)  
CDER, FDA
### FDA PARTICIPANTS (Non-Voting) (cont.)

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Division/Office</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ann Farrell, MD</strong></td>
<td>Director</td>
<td>Division of Hematology Products (DHP)</td>
</tr>
<tr>
<td>(Participation in afternoon session)</td>
<td></td>
<td>OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td><strong>Kathy Robie-Suh, MD, PhD</strong></td>
<td>Medical Team Leader</td>
<td>DHP, OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>(Participation in afternoon session)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rosanna Setse, MD, MPH, PhD</strong></td>
<td>Medical Officer</td>
<td>DHP, OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>(Participation in afternoon session)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Che Smith, PhD</strong></td>
<td>Statistical Reviewer</td>
<td>DBV, OB, OTS, CDER, FDA</td>
</tr>
<tr>
<td>(Participation in afternoon session)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>